Make your voice heard. Learn about 340B legislation at the state level and federal reform efforts in Washington.

Prohibitions Against Discriminatory Practices Related to 340B Entities and Drugs

HB 1281
Read the Bill

• 1/8/26 – Introduced
• 1/13/26 – First Reading
• 1/15/26 – Referred to Health Care Facilities & Systems Subcommittee, Insurance & Banking Subcommittee, and Health & Human Services Committee
• 3/13/26 – Died in Health Care Facilities & Systems Subcommittee

SB 1638
Read the Bill

• 1/9/26 – Filed
• 1/16/26 – Referred to Banking & Insurance; Health Policy; Rules
• 1/22/26 – Introduced
• 3/13/26 – Died in Banking and Insurance

Requires an audit of the 340B program in Illinois.

HB4327

Read the Bill

• 1/7/26 – Introduced
• 1/14/26 – Referred to Rules Committee
• 2/11/26 – Assigned to Executive Committee
• 3/27/26 – Rule 19(a) – Re-referred to Rules Committee
• 5/21/26 – Chief Sponsor Changed to Rep. Camille Y. Lilly
• 5/22/26 – Assigned to Executive Committee
• 5/22/26 – Committee 3rd Reading Deadline Extended-Rule May 31, 2026
• 5/22/26 – House Committee Amendment No. 1 Filed with Clerk by Rep. Camille Y. Lilly
• 5/22/26 – House Committee Amendment No. 1 Referred to Rules Committee
• 5/25/26 – House Committee Amendment No. 1 Rules Refers to Executive Committee
• 5/25/26 – Motion Filed to Suspend Rule 21 Executive Committee; Rep. Elizabeth “Lisa” Hernandez
• 5/25/26 – Motion to Suspend Rule 21 – Prevailed 066-029-000
• 5/26/26 – House Committee Amendment No. 1 Adopted in Executive Committee; by Voice Vote
• 5/26/26 – Do Pass as Amended / Short Debate Executive Committee; 008-004-000
• 5/26/26 – Placed on Calendar 2nd Reading – Short Debate
• 5/26/26 – House Floor Amendment No. 2 Filed with Clerk by Rep. Camille Y. Lilly
• 5/26/26 – House Floor Amendment No. 2 Referred to Rules Committee
• 5/26/26 – Second Reading – Short Debate
• 5/26/26 – Held on Calendar Order of Second Reading – Short Debate
• 5/27/26 – House Floor Amendment No. 2 Rules Refers to Executive Committee
• 5/28/26 – House Floor Amendment No. 2 Recommends Be Adopted Executive Committee; 008-004-000
• 5/28/26 – House Floor Amendment No. 3 Filed with Clerk by Rep. Camille Y. Lilly
• 5/28/26 – House Floor Amendment No. 3 Referred to Rules Committee
• 5/28/26 – House Floor Amendment No. 3 Recommends Be Adopted Rules Committee; 003-002-000
• 5/28/26 – House Floor Amendment No. 2 Adopted
• 5/28/26 – House Floor Amendment No. 3 Adopted by Voice Vote
• 5/28/26 – Placed on Calendar Order of 3rd Reading – Short Debate
• 5/28/26 – Third Reading – Short Debate – Passed 075-037-000
• 5/28/26 – Added Co-Sponsor Rep. Dagmara Avelar
• 5/28/26 – Added Co-Sponsor Rep. Maura Hirschauer
• 5/28/26 – Added Co-Sponsor Rep. Maurice A. West, II
• 5/28/26 – Addded Co-Sponsor Rep. Margaret A DeLaRosa
• 5/28/26 – Added Co-Sponsor Rep. Janet Yang Rohr
• 5/28/26 – Added Co-Sponsor Rep. Norma Hernandez
• 5/28/26 – Added Co-Sponsor Rep. Laura Faver Dias
• 5/29/26 – Arrive in Senate
• 5/29/26 – Placed on Calendar Order of First Reading
• 5/29/26 – Chief Senate Sponsor Sen. David Koehler
• 5/29/26 – SENATE First Reading
• 5/29/26 – Referred to Assignments
• 5/29/26 – Added Co-Sponsor Rep Barbara Hernandez
• 5/29/26 – Added Co-Sponsor Rep Michael J. Kelly
• 5/30/26 – Rule 2-10 Committee/3rd Reading Deadline Established As May 31, 2026
• 5/30/26 – Assigned to Executive
• 5/30/26 – Senate Committee Amendment No. 1 Filed with Secretary by Sen. David Koehler
• 5/30/26 – Senate Committee Amendment No. 1 Referred to Assignments
• 5/30/26 – Senate Committee Amendment No. 1 Assignments Refers to Executive
• 5/30/26 – Waive Posting Notice
• 5/30/26 – Senate Committee amendment No. 1 Adopted
• 5/30/26 – Do Pass as Amended Executive; 013-000-000
• 5/30/26 – Placed on Calendar Order of 2nd Reading
• 5/30/26 – Added as Alternate Chief Co-Sponsor Sen. Bill Cunningham
• 5/30/26 – Second Reading
• 5/30/26 – Placed on Calendar Order of 3rd Reading May 31, 2026
• 5/31/26 – Added as Alternate Co-Sponsor Sen. Michael W. Halpin
• 5/31/26 – Third Reading – Passed; 057-000-000
• 5/31/26 – Added as Alternate Co-Sponsor Sen. Robert F. Martwick
• 5/31/26 – Added as Alternate Co-Sponsor Sen. Mary Edly-Allen
• 5/31/26 – Arrived in House
• 5/31/26 – Placed on Calendar Order of Concurrence Senate Amendments(s) 1
• 5/31/26 – Added Chief Co-Sponsor Rep. Martha Deuter
• 5/31/26 – Senate Committee Amendment No. 1 Motion Filed Concur Rep. Camille Y. Lilly
• 5/31/26 – Senate Committee Amendment No. 1 Motion to Concur Referred to Rules Committee
• 5/31/26 – Added Co-Sponsor Rep. Emanuel “Chris” Welch
• 5/31/26 – Senate Committee Amendment No. 1 Motion to Concur Recommends Be Adopted Rules Committee; 004-000-000
• 5/31/26 – Senate Committee Amendment No. 1 House Concurs 106-008-000
• 5/31/26 – House Concurs
• 5/31/26 – Passed Both Houses
• 6/01/26 – Added Chief Co-Sponsor Rep. Anna Moeller
• 6/01/26 – Added Chief Co-Sponsor Rep. La Shawn K. Ford
• 6/01/26 – Added Co-Sponsor Rep. Kimberly Du Buclet
• 6/01/26 – Added Co-Sponsor Rep. Jehan Gordon-Booth
• 6/01/26 – Added Co-Sponsor Rep. Lisa Davis
• 6/01/26 – Added Co-Sponsor Rep. William “Will” Davis
• 6/01/26 – Added Co-Sponsor Rep. Rita Mayfield
• 6/01/26 – Added Co-Sponsor Rep. Justin Slaughter
• 6/01/26 – Added Co-Sponsor Rep. Sonya M. Harper
• 6/01/26 – Added Co-Sponsor Rep. Michael Crawford
• 6/01/26 – Added Co-Sponsor Rep. Yolanda Morris
• 6/01/26 – Added Co-Sponsor Rep. Debbie Meyers-Martin
• 6/01/26 – Added Co-Sponsor Rep. Carol Ammons
• 6/01/26 – Added Co-Sponsor Rep. Mary Beth Canty
• 6/01/26 – Added Co-Sponsor Rep. Marcus C. Evans, Jr.
• 6/01/26 – Added Co-Sponsor Rep. Bob Morgan
• 6/01/26 – Added Co-Sponsor Rep. Thaddeus Jones
• 6/01/26 – Added Co-Sponsor Rep. Suzanne M. Ness
• 6/01/26 – Added Co-Sponsor Rep. Robyn Gabel
• 6/01/26 – Added Co-Sponsor Rep. Lilian Jimenez
• 6/01/26 – Added Co-Sponsor Rep. Angelica Guerrero-Cuellar
• 6/01/26 – Added Co-Sponsor Rep. Nicolle Grasse
• 6/01/26 – Added as Alternate Co-Sponsor Sen. Elgie R. Sims, Jr.

Regulation of 340B Drug Manufacturers and Distributors

HF 2009
Read the Bill

• 1/13/26 – Introduced + Referred to Health and Human Services
• 1/14/26 – Assigned to Subcommittee
• 1/21/26 – Subcommittee recommends passage

Prohibiting Discrimination Against 340B Drug Entities

H.785
Read the Bill

• 3/31/25 – Referred to Financial Services
• 6/3/25 – Joint Hearing
• 9/18/25 – Reported Favorably + Referred to Health Care Financing
• 12/8/25 – Reporting date extended to 3/8/26
• 3/19/26 – Reporting date extended to Monday, June 15, 2026

H.1296
Read the Bill

• 6/3/25 – Joint Hearing

H.4495
Read the Bill

• 9/18/25 – Reported from Financial Services + Referred to Health Care Financing
• 12/8/25 – Reporting date extended to 3/8/26
• 3/19/26 – Reporting date extended to Monday, June 15, 2026

S.779
Read the Bill

• 6/3/25 – Joint Hearing
• 12/4/25 – Senate Study Order

Prohibitions Against Discriminatory Practices Related to 340B Entities and Drugs

HB 4878
Read the Bill

• 9/11/25 – Introduced and referred to Committee on Health Policy
• 1/28/26 – Reported with recommendation for referral to Committee on Rules
• 1/28/26 – Recommendation concurred

SB 94
Read the Bill

• 2/20/25 – Introduced and referred to Committee on Oversight
• 2/26/25 – Reported Favorably Without Amendment & Referred to Committee of the Whole
• 3/5/25 – Reported Favorably Without Amendment
• 3/6/25 – PASSED Senate 33-3
• 3/6/25 – Received by House and Referred to Committee on Health Policy

Prescription Drugs Delivery Restrictions Prohibition

SF 3769

• 02/23/26 – Introduction and first reading
• 02/23/26 – Referred to Commerce and Consumer Protection
• 02/26/26 – Author added Dahms
• 03/05/26 – Comm report: to pass and re-referred to Judiciary and Public Safety
• 03/23/26 – Comm report: To pass
• 03/23/36 – Second reading
• 04/07/26 – Special Order
• 04/07/26 – Third reading Passed
• 04/09/26 – Received to House from Senate
• 04/09/26 – Senate file First Reading, referred to Health Finance and Policy

Disallowance of drug manufacturers from restricting delivery of 340B prescription drugs continued, enforcement provided, and expiration date removed

HF 3609

• 02/23/26 – Introduction and first reading
• 02/23/26 – Referred to Health and Finance Policy
• 02/25/26 – Author stricken Gillman
• 02/26/26 – Authors added Norris, Johnson, P., and Swedzinski
• 03/02/26 – Author added Rehrauer
• 03/05/26 – Author added Gander
• 03/12/26 – Author stricken Perryman
• 03/12/26 – Authors added Warwas, Skraba, and Davis
• 03/16/26 – Author Anderson, P.H.
• 03/18/26 – Author added Keeler
• 03/23/26 – Motion to recall and re-refer, motion did not prevail Commerce Finance and Policy
• 03/25/26 – Author stricken Schomacker
• 04/16/26 – Author added Baker
• 04/28/26 – Author added Repinski

Missouri 340B Drug Pricing Program Reporting

HB 2081
Read the Bill

• 12/1/25 – Prefiled
• 1/7/26 – Read First Time
• 1/8/26 – Read Second Time
• 5/15/26 – Referred: Emerging Issues (H)

SB 1213
Read the Bill

• 12/1/25 – Prefiled
• 1/7/26 – Read First Time
• 1/27/26 – Second Read and Referred S Families, Seniors, and Health Committee
• 2/4/26 – Hearing conducted S Families, Seniors, and Health Committee

SB 1178 
Read the Bill

• 12/1/25 – Prefiled
• 1/7/26 – Read First Time
• 1/27/26 – Second Read and Referred S Families, Seniors, and Health Committee
• 2/4/26 – Hearing conducted S Families, Seniors, and Health Committee

Prohibiting Discrimination Against 340B Drug Entities by Insurers and PBMs

SB 1340
Read the Bill

• 12/1/25 – Prefiled
• 1/7/26 – Read First Time
• 1/27/26 – Second Read and Referred S Families, Seniors, and Health Committee

SB 846
Read the Bill

• 12/1/25 – Prefiled
• 1/7/26 – Read First Time
• 1/8/26 – Referred to Insurance and Banking Committee

Increasing Transparency in the 340B Drug Pricing Program

HB 1755
Read the Bill

• 1/7/26 – Introduced and Referred to Health, Human Services and Elderly Affairs Committee
• 1/21/26 – Public Hearing – 11:30AM
• 1/28/26 – Refer to Interim Study
• 2/12/26 – Motion adopted Voice Vote

SB 477
Read the Bill

• 1/7/26 – Introduced and Referred to Health and Human Services Committee
• 1/21/26 – Hearing – 1:30PM
• 2/12/26 – Committee Report – Referred to Interim Study
• 2/19/26 – Vote 5-0; Consent Calendar; Senate Calendar 6
• 2/19/26 – Removed from Consent Calendar; Senate Journal 4
• 2/19/26 – Special Order to the Next Session, Without Objection, Motion Adopted – Senate Journal 4
• 2/19/26 – Referred to Interim Study, 3/5/26, Vote 5-0; Senate Calendar 8
• 3/5/26 – Vote 5-0; Committee Report: Referred to Interim Study

340B Prescription Drug Anti-Discrimination Act

A6222
Read the Bill

• 1/7/26 – Referred to Health

S1913
Read the Bill

• 1/7/26 – Referred to Health
• 1/27/26 – Reported and committed to Finance

Prohibiting Restrictions on Contract Pharmacies

SB 278
Read the Bill

• 1/13/26 – Introduced and Referred to Committee on Education and Health
• 1/20/26 – Assigned to Subcommittee on Health
• 1/29/26 – Reported from Education and Health Committee with substitute; referred to Finance and Appropriations Committee
• 2/11/26 – Reported from Finance and Appropriations with substitute
• 2/12/26 – Rules suspended
• 2/12/26 – Constitutional reading dispensed Block Vote (on 1st reading)
• 2/12/26 – Passed by for the day Block Vote (Voice Vote)
• 2/13/26 – Committee substitute printed 26107756D-S2
• 2/13/26 – Read second time
• 2/13/26 – Committee substitute rejected (Voice Vote)
• 2/13/26 – Committee substitute agreed to (Voice Vote)
• 2/13/26 – Engrossed by Senate – committee substitute (Voice Vote)
• 2/16/26 – Read third time and passed Senate
• 2/19/26 – Placed on Calendar
• 2/19/26 – Read first time
• 2/19/26 – Referred to Committee on Health and Human Services
• 2/23/26 – Assigned sub: Health
• 2/23/26 – Fiscal Impact Statement from Department of Planning and Budget (SB278)
• 2/24/26 – House subcommittee offered
• 3/2/26 – Read second time
• 3/3/26 – Read third time
• 3/3/26 – Health and Human Services amendments agreed
• 3/3/26 – Engrossed by House as amended
• 3/3/26 – Passed House with amendments Block Vote (39 Y – 0 N, 0 A)
• 3/5/26 – House amendments agreed to by Senate (39 Y, 0 N, 0 A)
• 3/11/26 – Enrolled
• 3/11/26 – Bill text as passed Senate and House (SB278ER)
• 3/11/26 – Fiscal Impact Statement from Department of Planning and Budget (SB278)
• 3/11/26 – Signed by President
• 3/12/26 – Signed by Speaker
• 3/14/26 – Enrolled Bill communicated to Governor on March 14, 2026
• 3/14/26 – Governor’s Action Deadline 11:59 p.m., April 13, 2026
• 4/13/26 – Approved by Governor – Chapter 887 (effective 7/1/26)
• 4/13/26 – Acts of Assembly Chapter text (CHAP0887)

Protecting Patient Access to Discounted Medications via 340B Program

SB 5981
Read the Bill

• 1/5/26 – Prefiled
• 1/12/26 – Read First Time + Referred to Health & Long Term Care
• 1/16/26 – Hearing: 8AM
• 1/27/26 – Recommended do pass
• 1/28/26 – Referred to Ways & Means
• 2/5/26 – Public hearing in the Senate Committee on Ways & Means at 1:30 PM.
• 2/9/26 – Executive action taken in the Senate Committee on Ways & Means at 10:30 AM.
• 2/9/26 – WM – Majority; 2nd substitute bill be substituted, do pass.
• 2/9/26 – Minority; do not pass.
• 2/9/26 – Minority; without recommendation.
• 2/9/26 – Passed to Rules Committee for second reading.
• 2/10/26 – Placed on second reading by Rules Committee.
• 2/13/26 – 2nd substitute bill substituted
• 2/13/26 – Floor Amendments Adopted
• 2/13/26 – Rules suspended. Placed on Third Reading.
• 2/13/26 – Third reading, passed; yeas, 30; nays, 18; absent, 0; excused, 1
• 2/17/26 – First reading, referred to Health Care & Wellness.
• 2/20/26 – Public hearing in the House Committee on Health Care & Wellness at 8:00 AM.
• 2/25/26 – Executive action taken in the House Committee on Health Care & Wellness at 1:30 PM.
• 2/25/26 – HCW – Majority; do pass with amendment(s)
• 2/25/26 – Minority; do not pass.
• 2/25/26 – Minority; without recommendation.
• 2/25/26 – Referred to Appropriations.

HB 2145
Read the Bill

• 12/15/25 – Prefiled
• 1/12/26 – Read First Time + Referred to Health Care & Wellness
• 1/23/26 – Recommended do pass
• 1/28/26 – Referred to Appropriations
• 2/6/26 – Public hearing in the House Committee on Appropriations at 10:30 AM
• 2/9/26 – Executive action taken in the House Committee on Appropriations at 10:30 AM.
• 2/9/26 – APP – Majority; 2nd substitute bill be substituted, do pass
• 2/9/26 – Minority; do not pass.
• 2/9/26 – Minority; without recommendation.
• 2/9/26 – Referred to Rules 2 Review.